Compare Inovio Pharmaceuticals Inc (INO) vs Ryanair Holdings plc (RYAAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Ryanair Holdings plc — how do they compare? Inovio Pharmaceuticals Inc trades at $1.15 (market cap $112.19M), while Ryanair Holdings plc trades at $54.24 (market cap $27.11B). The key difference: Ryanair Holdings plc is far larger — about 241.6× Inovio Pharmaceuticals Inc's market cap, and Ryanair Holdings plc pays a 1.66% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Ryanair Holdings plc for 72 Days on average.
| INO | RYAAY | |
|---|---|---|
Market Cap | $112.19M | $27.11B |
Volume | 3,201,278 | 2,427,380 |
Sector | Health | Industrials |
52-Week High | $2.60 | $73.82 |
52-Week Low | $0.66 | $51.95 |
Typical Hold Time | 43 Days | 72 Days |
Enterprise Value | $83.51M | $24.18B |
Dividend Yield | — | 1.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.09, down 5.63% today, with a bearish technical outlook and negative financial metrics including a net income margin of -130,000% and ROE of -409.87%. The company faces significant fundamental challenges with minimal revenue of $65,340 and substantial losses, though recent earnings have beaten expectations. Key near-term catalyst is the FDA decision on INO-3107 by October 30, 2026.
Despite analyst consensus favoring Buy ratings (58.83%) with a $2.75 price target, INO carries high risk due to persistent cash burn, negative profitability, and dependency on regulatory approvals. The stock offers speculative upside if INO-3107 gains approval but remains vulnerable to further dilution and operational setbacks.
RYAAY trades at $54.04, down 3.5% today, with technical indicators showing bearish momentum. The stock shows strong fundamentals with $13.95B revenue, 12.13% net margin, and attractive valuation at P/E 13.43. Recent earnings show mixed results with Q1 beat but Q2 miss. Analyst consensus remains positive with 65% buy ratings despite near-term headwinds from fuel costs and Boeing MAX 10 certification delays.
RYAAY presents a value opportunity with solid profitability and growth prospects, though investors face near-term risks from volatile fuel prices and operational challenges. The airline's low-cost leadership and market share gains support long-term upside, but winter capacity cuts and unhedged oil exposure require careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Ryanair Holdings plc
Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Read more on RYAAY →
